Drug Approval | November 21, 2025
Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The move is expected to be crucial during health crises
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
This is the first drug to receive a recommendation for this preventative indication in the European Union
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Enabling a new era in minimally invasive obesity treatment across Europe
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Subscribe To Our Newsletter & Stay Updated
